Lilly Ventures
Profile, fund size and portfolio
Lilly Ventures is the corporate venture arm of Eli Lilly and Company (pharmaceuticals). It was founded in 2001 and is based in Indianapolis, United States. It invests from Seed to Series A in therapeutics, healthtech, impact investing.
- Assets under managementS2
- USD 2bn+
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Seed to Series A |
| Sectors | Therapeutics, Healthtech, Impact investing |
| Geography | Worldwide ; impact portfolio targets underserved patients in the US and globally |
| Offices | Indianapolis, United States |
Sources: S1 Global Venturing: Powerlist 2026, Brad Robling; S2 Global Venturing: Emerging Leaders 2026, Laura Daily.
Data behind this graphic
The firm has not published a portfolio breakdown.
Sources: .
Where it invests and who leads it
Geography
- Headquarters
- Indianapolis, United States
- Offices
- Indianapolis, United States
Investment regionsS1S2
- Worldwide ; impact portfolio targets underserved patients in the US and globally
LeadersS6S2
- Brad RoblingGlobal Head, Lilly VenturesFind on LinkedInFirm page
- Laura DailyDirector, impact investingFind on LinkedInFirm page
- Nisha NandaGroup VP, Head of Lilly Catalyze360Find on LinkedInFirm page
- Jim MacKrell, PhDLilly Venture Science Global HeadFind on LinkedInFirm page
Profile in progress. This firm does not yet meet our publishing minimum: sources, website, launch year, leaders. It is not indexed by search engines until it does.
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Eli Lilly and Company | Single source | S1 |
| Parent industry | Pharmaceuticals | Single source | S1 |
| Founded | 2001 | Single source | S7 |
| Headquarters | Indianapolis, United States | Single source | S4 |
| Status | Active | Single source | S1 |
| Capital source | Parent company only | Single source | S2 |
| Headline size | USD 2bn+ (Assets under management) | Single source | S2 |
| Stages | Seed, Series A | Single source | S1 |
Fund vehicles
| Vehicle | Size | Year | Note | Source |
|---|---|---|---|---|
| Social Impact Venture Capital Portfolio (impact, fund of funds) | USD 300M | GCV: dedicated fund poised to grow to $300m; Daily: $300m fund-of-funds portfolio | S1 | |
| Biotech Ecosystem Venture Fund (managed by a16z Bio + Health, Lilly partner) | USD 500M | 2025 | Up to $500 million; announced 2025-02-07 | S3 |
| Tech-focused fund started 2023 (name not given) | Not published | 2023 | GCV Powerlist | S1 |
For founders
Recent rounds
| Date | Company | Round | Amount | Led by the firm | Source |
|---|---|---|---|---|---|
| Remedium Bio | Series A | USD 10M | S1 |
History
Where sources disagree
Official pages
Read the firm's own pages for current information.
Sources
- S1Global Venturing: Powerlist 2026, Brad RoblingPress
- S2Global Venturing: Emerging Leaders 2026, Laura DailyPress
- S3HLTH: Andreessen Horowitz and Eli Lilly launch $500M Biotech Ecosystem FundPress
- S4SEC EDGAR: Lilly Ventures Fund I LLC (Form D filer, Indianapolis)Filing
- S5Lilly Catalyze360 page (names Lilly Ventures as global investment arm)Firm
- S6Lilly partnering team page: Lilly Ventures Global Head and Venture Science headsFirm
- S7Indianapolis Business Journal: Lilly reorganizes venture capital unit (formed in 2001)Press
- S8RaiseHunt: Lilly Ventures portfolio list (third-party; Lilly publishes no portfolio list)Third-party report
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by Lilly Ventures or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.